The effect of omega-3 poly-unsaturated fatty acid supplements in patients with Psoriasis vulgaris has previously been investigated, but interventions varied in source, composition, dose, administration route and duration of treatment. The observed beneficial effects in patients with Psoriasis vulgaris using herring roe oil (HRO) as a dietary supplement prompted the conduct of this investigation. We monitored the longer-term efficacy and safety of as oral treatment for patients with plaque psoriasis originally included with a Psoriasis Area Severity Index (PASI) < 10 in a 39-week open-label extension period following a 26 week double-blind randomised and placebo controlled study (ClinicalTrials.gov: NCT03359577, date: 02 December 2017). All patients in the randomised study who were still participating at week 26 were invited to continue on active treatment. Fifty-eight of 64 patients included in the randomised study, were all treated with HRO through the extension period; 28 subjects from the HRO group and 30 subjects from the placebo group. Change (mean ± standard deviation; SD) in the PASI score from baseline in the 26 week double-blind period was -2.13±2.57 in the HRO-HRO group and -0.63±1.87 in the placebo-HRO group, and the difference between the groups was statistically significant (p<0.05). At conclusion of the entire 65-week period (15 months), the change in PASI was -3.44±1.83 in the HRO-HRO group and -3.06±1.69 in the placebo-HRO group. The secondary variables showed decreasing disease symptoms and clinically meaningful patient reported outcomes as shown with a mean reduction in Dermatological Life Quality Index (DLQI) score of >4 points. The most commonly reported adverse events in both groups were gastrointestinal in nature. No serious adverse reactions were reported.
| Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 7, Issue 1) |
| DOI | 10.11648/j.ijcems.20210701.13 |
| Page(s) | 13-20 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Herring Roe Oil, Psoriasis, Omega-3, Phospholipids
| [1] | Boehncke W-H. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018; 9: 579. |
| [2] | Bjørndal B, Strand E, Gjerde J, Bohov P, Svardal A, Diehl BW, et al. Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids Health Dis. 2014 May 17; 13: 82. |
| [3] | Cook CM, Hallaråker H, Sæbø PC, Innis SM, Kelley KM, Sanoshy KD, et al. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols. Prostaglandins Leukot Essent Fatty Acids. 2016; 111: 17–24. |
| [4] | Khorsan R, Crawford C, Ives JA, Walter AR, Jonas WB. The effect of omega-3 fatty acids on biomarkers of inflammation: a rapid evidence assessment of the literature. Mil Med. 2014 Nov; 179 (11 Suppl): 2–60. |
| [5] | Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta. 2010 Dec; 1801 (12): 1260–73. |
| [6] | Tveit KS, Brokstad KA, Berge RK, Sæbø PC, Hallaråker H, Brekke S, et al. A Randomized, Double-blind, Placebo-controlled Clinical Study to Investigate the efficacy of Herring Roe Oil for treatment of Psoriasis. Acta Derm Venereol. 2020 May 28; 100 (10): adv00154. |
| [7] | Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157 (4): 238–44. |
| [8] | Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005 Mar; 64 Suppl 2: ii65-68; discussion ii69-73. |
| [9] | Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013 Oct; 149 (10): 1180–5. |
| [10] | Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May; 19 (3): 210–6. |
| [11] | Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan; 303 (1): 1–10. |
| [12] | Puzenat E, Bronsard V, Prey S, Gourraud P-A, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol JEADV. 2010 Apr; 24 Suppl 2: 10–6. |
| [13] | Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data. Dermatology. 2015; 230 (1): 27–33. |
| [14] | Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008 Nov; 159 (5): 997–1035. |
| [15] | Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol. 2002; 147 (50). |
| [16] | Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19; 323 (19): 1945–60. |
| [17] | Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primer. 2016 24; 2: 16082. |
| [18] | Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020 09; 1: CD011535. |
APA Style
Kaare Steinar Tveit, Karl Albert Brokstad, Rolf Kristian Berge, Per Christian Saeboe, Hogne Hallaraaker, et al. (2021). Long Term Efficacy and Safety of Herring Roe Oil in the Treatment of Psoriasis, a 39-week Open-label Extension Study. International Journal of Clinical and Experimental Medical Sciences, 7(1), 13-20. https://doi.org/10.11648/j.ijcems.20210701.13
ACS Style
Kaare Steinar Tveit; Karl Albert Brokstad; Rolf Kristian Berge; Per Christian Saeboe; Hogne Hallaraaker, et al. Long Term Efficacy and Safety of Herring Roe Oil in the Treatment of Psoriasis, a 39-week Open-label Extension Study. Int. J. Clin. Exp. Med. Sci. 2021, 7(1), 13-20. doi: 10.11648/j.ijcems.20210701.13
AMA Style
Kaare Steinar Tveit, Karl Albert Brokstad, Rolf Kristian Berge, Per Christian Saeboe, Hogne Hallaraaker, et al. Long Term Efficacy and Safety of Herring Roe Oil in the Treatment of Psoriasis, a 39-week Open-label Extension Study. Int J Clin Exp Med Sci. 2021;7(1):13-20. doi: 10.11648/j.ijcems.20210701.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcems.20210701.13,
author = {Kaare Steinar Tveit and Karl Albert Brokstad and Rolf Kristian Berge and Per Christian Saeboe and Hogne Hallaraaker and Stian Brekke and Nils Meland and Bodil Bjoerndal},
title = {Long Term Efficacy and Safety of Herring Roe Oil in the Treatment of Psoriasis, a 39-week Open-label Extension Study},
journal = {International Journal of Clinical and Experimental Medical Sciences},
volume = {7},
number = {1},
pages = {13-20},
doi = {10.11648/j.ijcems.20210701.13},
url = {https://doi.org/10.11648/j.ijcems.20210701.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20210701.13},
abstract = {The effect of omega-3 poly-unsaturated fatty acid supplements in patients with Psoriasis vulgaris has previously been investigated, but interventions varied in source, composition, dose, administration route and duration of treatment. The observed beneficial effects in patients with Psoriasis vulgaris using herring roe oil (HRO) as a dietary supplement prompted the conduct of this investigation. We monitored the longer-term efficacy and safety of as oral treatment for patients with plaque psoriasis originally included with a Psoriasis Area Severity Index (PASI) 4 points. The most commonly reported adverse events in both groups were gastrointestinal in nature. No serious adverse reactions were reported.},
year = {2021}
}
TY - JOUR T1 - Long Term Efficacy and Safety of Herring Roe Oil in the Treatment of Psoriasis, a 39-week Open-label Extension Study AU - Kaare Steinar Tveit AU - Karl Albert Brokstad AU - Rolf Kristian Berge AU - Per Christian Saeboe AU - Hogne Hallaraaker AU - Stian Brekke AU - Nils Meland AU - Bodil Bjoerndal Y1 - 2021/01/22 PY - 2021 N1 - https://doi.org/10.11648/j.ijcems.20210701.13 DO - 10.11648/j.ijcems.20210701.13 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 13 EP - 20 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20210701.13 AB - The effect of omega-3 poly-unsaturated fatty acid supplements in patients with Psoriasis vulgaris has previously been investigated, but interventions varied in source, composition, dose, administration route and duration of treatment. The observed beneficial effects in patients with Psoriasis vulgaris using herring roe oil (HRO) as a dietary supplement prompted the conduct of this investigation. We monitored the longer-term efficacy and safety of as oral treatment for patients with plaque psoriasis originally included with a Psoriasis Area Severity Index (PASI) 4 points. The most commonly reported adverse events in both groups were gastrointestinal in nature. No serious adverse reactions were reported. VL - 7 IS - 1 ER -
Information
Email: